who remain symptomatic despite H1 antihistamine treatment. Cosentyx (secukinumab) is a human monoclonal antibody that selectively neutralizes circulating interleukin 17A (IL-17A). In 2014, Cosentyx was approved in Japan for the treatment of both psoriasis vulgaris and psoriatic arthritis in adults who are not adequately responding to systemic therapies (except for biologics). In January 2015, Cosentyx was approved in the EU as a systemic treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy; and in the U.S .as a treatment for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. In addition to the EU and the U.S., Cosentyx has been approved and launched in Switzerland, Canada, Australia, and various other markets for the treatment of moderate-to-severe plaque psoriasis. In November 2015, Cosentyx was approved in the EU for the treatment of adults with ankylosing spondylitis who have responded inadequately to conventional therapy, such as non-steroidal anti-inflammatory drugs, and for the treatment of active psoriatic arthritis in adults when the response to disease modifying anti-rheumatic drug therapy is unsatisfactory. In Japan, Cosentyx is approved for the treatment of moderate-to-severe plaque psoriasis, as well as psoriatic arthritis. In December 2015, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved Cosentyx for the treatment of patients with pustular psoriasis. In January 2016, Cosentyx was approved in the U.S. for the treatment of adults with active ankylosing spondylitis and for the treatment of adults with active psoriatic arthritis. Retina Lucentis (ranibizumab) is a recombinant humanized high affinity antibody fragment that binds to vascular endothelial growth factors (VEGF). It is an anti-VEGF therapy licensed in various countries for five ocular indications, such as neovascular age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema (DME), visual impairment due to macular edema secondary to branch retinal vein occlusion, visual impairment due to macular edema secondary to central retinal vein occlusion, and visual impairment due to choroidal neovascularization secondary to pathologic myopia (myopic CNV). Lucentis is approved in approximately 100 countries to treat patients with nAMD, for the treatment of visual impairment due to DME and macular edema secondary to RVO. Also, Lucentis is licensed in 80 countries for the treatment of visual impairment due to myopic CNV. The company licensed Lucentis from Genentech Inc. for development and commercialization outside of the U.S. Respiratory Xolair (omalizumab) is a humanized monoclonal antibody approved for the treatment of moderate to severe persistent allergic asthma in the U.S. in adolescents (aged 12 and above) and adults. Xolair is approved in approximately 90 countries, including the U.S. and the EU. It is approved for severe persistent allergic asthma in the EU in children (aged six and above), adolescents, and adults. A liquid formulation of Xolair in pre-filled syringes is launched in various European countries. In Japan, Xolair was approved in January 2009 for the treatment of severe persistent allergic asthma in adults (aged 15 and older) and was approved in 2013 in pediatric patients aged 6 years or older for the same indication. Xolair was submitted to the FDA in December 2015 for pediatric allergic asthma. Ultibro Breezhaler (indacaterol/glycopyrronium bromide)/Utibron Neohaler (indacaterol/glycopyrrolate) is a fixed-dose combination of the long-acting beta2-adrenergic agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide. Ultibro Breezhaler (indacaterol 85 mcg/glycopyrronium 43 mcg), inhalation powder, hard capsules was approved in the EU in 2013 as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD); and in Japan the MHLW approved Ultibro inhalation capsules (glycopyrronium 50 mcg/indacaterol 110 mcg), delivered through the low resistance Bre
novartis ag-sponsored adr (NVS:New York)
Phone: 41 61 324 11 11
Fax: 41 61 324 80 01www.novartis.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for NVS.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.